Page 2 - Metacrine Company Profile Get Rating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Metacrine company profile get rating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Metacrine Company Profile Get Rating Today - Breaking & Trending Today

Metacrine (NASDAQ:MTCR) Downgraded by Zacks Investment Research to "Hold"

Zacks Investment Research cut shares of Metacrine (NASDAQ:MTCR – Get Rating) from a buy rating to a hold rating in a research report report published on Thursday, Zacks.com reports. According to Zacks, “Metacrine Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing therapies for patients with liver and gastrointestinal diseases. The […] ....

United States , San Diego , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Virtu Financial , Zacks Investment Research , Renaissance Technologies , York Mellon Corp , Venture Management , Metacrine Inc , Get Rating , New York Mellon Corp , Sachs Group , Company Profile , Nasdaq Mtcr ,

Metacrine, Inc. (NASDAQ:MTCR) Sees Large Decline in Short Interest

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a significant drop in short interest during the month of April. As of April 30th, there was short interest totalling 808,600 shares, a drop of 33.7% from the April 15th total of 1,220,000 shares. Based on an average trading volume of 1,730,000 shares, the short-interest […] ....

United States , York Mellon Corp , Goldman Sachs Group Inc , Zacks Investment Research , Renaissance Technologies , Metacrine Inc , America Corp , Get Rating , New York Mellon Corp , Sachs Group , Nasdaq Mtcr ,

Metacrine, Inc. (NASDAQ:MTCR) CEO Sells $22,374.00 in Stock

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) CEO Preston Klassen sold 44,748 shares of the company’s stock in a transaction on Tuesday, April 19th. The stock was sold at an average price of $0.50, for a total value of $22,374.00. Following the completion of the sale, the chief executive officer now owns 922,510 shares of the […] ....

United States , Preston Klassen , Morgan Stanley , Goldman Sachs Group Inc , Zacks Investment Research , America Corp , Cim Investment Management Inc , Citadel Advisors , Metacrine Inc , Get Rating , Sachs Group , Cim Investment Management , Investment Management , Nasdaq Mtcr , Insider Trading , Nsider Trades ,

Metacrine Reports Fourth-Quarter 2021 Results

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated. ....

Preston Klassen , Exchange Commission , Drug Administration , Metacrine Inc , Private Securities Litigation Reform Act , Annual Report , Preferred Stock , Nasdaq Mtcr , Inflammatory Bowel Disease , Ulcerative Colitis ,

Metacrine, Inc. (NASDAQ:MTCR) Short Interest Update

Metacrine, Inc. (NASDAQ:MTCR – Get Rating) was the recipient of a large decrease in short interest in February. As of February 28th, there was short interest totalling 465,600 shares, a decrease of 20.9% from the February 13th total of 588,600 shares. Based on an average daily volume of 3,470,000 shares, the short-interest ratio is presently […] ....

Paul Edward Walker , Morgan Stanley , Securities Exchange Commission , Goldman Sachs Group Inc , Metacrine Company Profile Get Rating , Virtu Financial , Zacks Investment Research , Walleye Capital , Citadel Advisors , Metacrine Inc , Get Rating , Exchange Commission , Goldman Sachs Group , Sachs Group , Company Profile , Nasdaq Mtcr ,